Építés alatt – nem éles oldal
Belépés
Fut, nem toborozFázis nélkül

Clinical Trial to Evaluate the Efficacy and Safety of MegaCarti® in Knee Cartilage Defects

A legfontosabb adatok

Ki végzi
L&C Bio
Hol
Dél-Korea4 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Fut, nem toboroz
Résztvevők
90 fő vett részt
Kezdés
2020. ápr. 16.
Várható befejezés
2027. jan. 31.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • MegaCarti®
  • Microfracture
A regiszteradat frissítve
2022. június 30.

Ki vehet részt

Életkor
19 év – 65 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 22 feltétel megnézéseKevesebb

Ki vehet részt

  • 19 years to 65 years
  • Patients or legal representatives who voluntarily decide to participate in the clinical trial, after which sign the consent form
  • Defect: International Cartilage Repair Society(ICRS) Grade III or IV single defect chondral lesion on knee cartilage
  • Patients whose primary lesion site can be designated as one section of the knee joint, and the area can be determined as the main cause of clinical symptoms
  • knee cartilage defect size : Below 10 ㎠

Ki nem vehet részt

  • Patients who underwent surgery related to cartilage defect treatment, such as microfracture, autologous chondrocyte therapy within the past 1 year (Possible for HTO surgery)
  • When screening, Patients who received intra-articular hyaluronic acid or steroid injections in the knee within 3 months
  • When screening, Patients who took oral steroid within 1 month
  • Patients who participated in other clinical trials within three months before screening
  • Patients who have autoimmune diseases (Ex. Rheumatoid arthritis)
  • Patients taking immunosuppressive drug, or having immune disorder
  • Patients with a history of cancer within the past five years
  • Patients who have chronic renal failure, active hepatitis, or poor blood sugar control
  • Drug and alcohol addiction / dependence or mental disorder
  • Patients with risk factor for bleeding (Patients taking antithrombotic drugs other than aspirin)
  • Patients who have systemic or localized knee infection
  • When screening, Patients who have clinically significant abnormalities in blood, serum, or urine tests
  • Patients who can't take MRI scan
  • BMI index : 30 ㎏/㎡ or over
  • Patients who have gout or gout history in the knee
  • When screening, Women who are pregnant or breast-feeding, or women who are planning for pregnancy during the clinical trial, or women who have a possibility of pregnancy but do not use medically accepted methods of contraception
  • Other than above, patients who are judged by medical investigator to be considered unsuitable for this clinical trial

Hol van ez a vizsgálat?

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

The MegaCarti® is the decellularized allogeneic cartilage and acts as a cover after bone marrow stimulation to prevent the loss of blood clots and induces cartilage regeneration by assisting in the location of stem cells derived from bone marrow.

A teljes eredeti leírásKevesebb

The MegaCarti® is applied after Microfracture treatment on patients with Knee Cartilage Defects. The cartilage regeneration, which is a primary endpoint, is compared to the Microfracture group through MOCART evaluation. In addition, the improvement of pain and the recovery of Normal Range of motion are compared to the Microfracture group through secondary endpoints. Then, long-term follow-up study for 5 years is conducted to the experimental group.

A vizsgálat 2 csoportja

  • MegaCarti® application after microfractureA vizsgált kezelés

    The experimental group is applied with MegaCarti® after microfracture. Afterwards, they visit at 6 weeks, 12 weeks, 24 weeks, and 48 weeks to conduct examinations and assess Questionnaires. Long-term follow-up Study is performed to subject that completes 48-week visit, at every 6 months for 5 years.

    Kezelés: MegaCarti® és Microfracture

  • Microfracture onlyMár használt kezelés, összehasonlításként

    The control group undergoes microfracture and they visit at 6 weeks, 12 weeks, 24 weeks, and 48 weeks after surgery to conduct examinations and assess Questionnaires.

    Kezelés: Microfracture

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Clinical Trial to Evaluate the Efficacy and Safety of MegaCarti® ; Cartilage Defect Treatment Assisting Cartilage Regeneration in Knee Cartilage Defects : Multicenter, Independent Evaluator and Subject Blinded, Microfracture Comparative, Superiority, Randomized, Confirmatory Clinical Study and 5 Years Follow up Study
A regiszteradat frissítve
2022. június 30.